SG11201912233TA - Method for prediction of response to cardiovascular regeneration - Google Patents

Method for prediction of response to cardiovascular regeneration

Info

Publication number
SG11201912233TA
SG11201912233TA SG11201912233TA SG11201912233TA SG11201912233TA SG 11201912233T A SG11201912233T A SG 11201912233TA SG 11201912233T A SG11201912233T A SG 11201912233TA SG 11201912233T A SG11201912233T A SG 11201912233TA SG 11201912233T A SG11201912233T A SG 11201912233TA
Authority
SG
Singapore
Prior art keywords
prediction
response
cardiovascular regeneration
cardiovascular
regeneration
Prior art date
Application number
SG11201912233TA
Other languages
English (en)
Inventor
Gustav Steinhoff
Julia Nesteruk
Markus Wolfien
Original Assignee
Univ Rostock Zentrale Univsverwaltung Referat 1 1 Recht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rostock Zentrale Univsverwaltung Referat 1 1 Recht filed Critical Univ Rostock Zentrale Univsverwaltung Referat 1 1 Recht
Publication of SG11201912233TA publication Critical patent/SG11201912233TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/505—Erythropoietin [EPO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Ecology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
SG11201912233TA 2017-07-18 2018-07-16 Method for prediction of response to cardiovascular regeneration SG11201912233TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017116204.6A DE102017116204B4 (de) 2017-07-18 2017-07-18 Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
PCT/EP2018/069307 WO2019016156A1 (fr) 2017-07-18 2018-07-16 Procédé de prédiction de la réponse à une régénération cardiovasculaire

Publications (1)

Publication Number Publication Date
SG11201912233TA true SG11201912233TA (en) 2020-01-30

Family

ID=63012999

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912233TA SG11201912233TA (en) 2017-07-18 2018-07-16 Method for prediction of response to cardiovascular regeneration

Country Status (10)

Country Link
US (1) US11714093B2 (fr)
EP (1) EP3655775B1 (fr)
JP (1) JP7403162B2 (fr)
KR (1) KR102535577B1 (fr)
CN (1) CN110945357B (fr)
AU (1) AU2018302405A1 (fr)
CA (1) CA3069874A1 (fr)
DE (1) DE102017116204B4 (fr)
SG (1) SG11201912233TA (fr)
WO (1) WO2019016156A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018125324A1 (de) * 2018-10-12 2020-04-16 Universität Rostock Verfahren zur Vorhersage einer Antwort auf die Therapie von Krankheiten
DE102020205364B4 (de) * 2020-04-28 2022-01-20 Universität Rostock Verfahren zur Überwachung des Verlaufs einer Kardiomyozyten-Transplantation und Methode zur Bestimmung, ob ein Proband für einer Kardiomyozyten-Transplantation geeignet ist
US20230169651A1 (en) * 2020-04-30 2023-06-01 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods For Predicting Post-Operative Right Ventricular Failure Using Echocardiograms
IT202100011327A1 (it) * 2021-05-04 2022-11-04 Gek S R L Metodo prognostico

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
WO2007142288A1 (fr) 2006-06-07 2007-12-13 The University Of Tokushima Traitement d'une maladie ischémique à l'aide d'érythropoïétine
US8835163B2 (en) 2006-10-18 2014-09-16 The Board Of Trustees Of The University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
US8617877B2 (en) * 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
BRPI0920069A8 (pt) 2008-10-30 2017-10-03 Centre De Rech Public De La Sante Biomarcadores
US9446076B2 (en) 2009-05-20 2016-09-20 Cardio3 Biosciences S.A. Pharmaceutical composition for the treatment of heart diseases
SG10201913904PA (en) 2010-02-25 2020-03-30 Abt Holding Co Modulation of angiogenesis
GB201007159D0 (en) * 2010-04-29 2010-06-09 Nhs Blood & Transplant Method for evaluating anglogenic potential
CN101940591B (zh) * 2010-08-27 2013-09-18 上海士腾生物技术有限公司 促血管再生或新生的制剂及其制备方法
CN101940594B (zh) 2010-08-27 2013-12-04 上海士腾生物技术有限公司 用于治疗缺血性心血管疾病的制剂及其制备方法
TW201315479A (zh) 2011-10-12 2013-04-16 Univ Nat Cheng Kung 可促進動脈新生之醫藥組成物、及其製備方法與應用
EP2825882A1 (fr) 2012-03-16 2015-01-21 UMC Utrecht Holding B.V. Marqueurs biologiques pour remodelage cardiaque indésirable
GB201223058D0 (en) 2012-12-20 2013-02-06 Cardio3 Bioscience S A Biomarker methods and compositions
EP3413052B1 (fr) 2014-03-26 2022-12-28 Roche Diagnostics GmbH Igfbp7 permettant de diagnostiquer un dysfonctionnement diastolique

Also Published As

Publication number Publication date
US20200174020A1 (en) 2020-06-04
CN110945357A (zh) 2020-03-31
JP2020527710A (ja) 2020-09-10
WO2019016156A1 (fr) 2019-01-24
DE102017116204B4 (de) 2024-06-27
AU2018302405A1 (en) 2020-01-16
EP3655775A1 (fr) 2020-05-27
CN110945357B (zh) 2024-05-31
KR102535577B1 (ko) 2023-05-23
JP7403162B2 (ja) 2023-12-22
EP3655775C0 (fr) 2023-06-07
KR20200031121A (ko) 2020-03-23
DE102017116204A1 (de) 2019-01-24
EP3655775B1 (fr) 2023-06-07
US11714093B2 (en) 2023-08-01
CA3069874A1 (fr) 2019-01-24

Similar Documents

Publication Publication Date Title
HK1247542A1 (zh) 用於吸煙行為的量化和預測的系統和方法
HK1251689A1 (zh) 預測模型的動態執行
EP3167614A4 (fr) Procédé de calcul de vecteur de mouvement dérivé temporellement, pour une prédiction de vecteur de mouvement
HUE048265T2 (hu) Eljárás PD-L1 mennyiségi meghatározására
SG11201912233TA (en) Method for prediction of response to cardiovascular regeneration
GB201521357D0 (en) Methods for predicting response to anti-TNF therapy
HK1231556A1 (zh) 確定組織放射敏感性的預測方法
RS65740B1 (sr) Postupak pranja
GB2545068B (en) Method to reduce reactivation time of cloud based services
ZA201608555B (en) Biomarkers for response to ezh2 inhibitors
GB201504072D0 (en) Method of producing metal
GB201904142D0 (en) Improved method of FT-IMS
GB201522552D0 (en) Method of improving adhesion
GB2554576B (en) Method for determining nucleotide sequence by application of dynamic time warping
SG11201800894SA (en) Method for parallel quantification of protein variant
GB201512602D0 (en) Method of modelling biomarkers
IL239909A0 (en) Methods for treating cardiovascular signs
PL3075869T3 (pl) Sposób wytwarzania stopów żelazo - krzem - glin
GB2550139B (en) Functional prediction of MSCs
PL3265732T3 (pl) Sposób suszenia budowli
IL255320A0 (en) A method for determining system states using an evaluation filter
IL266902A (en) Method for reduction of oxo-halogen compounds
PL3371774T3 (pl) Sposób kwantyfikacji obrazów
HUE056117T2 (hu) Eljárás képek kvantálására
GB201612764D0 (en) Method to measure technical quality of movement